𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Retracted: Transactivation of CCL20 gene by Epstein–Barr virus latent membrane protein 1

✍ Scribed by Taeko Okudaira; Kazuo Yamamoto; Hirochika Kawakami; Jun-Nosuke Uchihara; Mariko Tomita; Masato Masuda; Takehiro Matsuda; Takeshi Sairenji; Hidekatsu Iha; Kuan-Teh Jeang; Toshifumi Matsuyama; Nobuyuki Takasu; Naoki Mori

Book ID
108673553
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
347 KB
Volume
132
Category
Article
ISSN
0007-1048

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Retracted: Transactivation of the CCL5/R
Retracted: Transactivation of the CCL5/RANTES gene by Epstein-Barr virus latent membrane protein 1
✍ Jun-Nosuke Uchihara; Alan M. Krensky; Takehiro Matsuda; Hirochika Kawakami; Taek 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 460 KB

## Abstract Retraction: The following article has been retracted through agreement between the first author and several coauthors, the journal Editor‐in‐Chief, Peter Lichter, and John Wiley & Sons, Ltd.: Uchihara JN, Krensky AM, Matsuda T, Kawakami H, Okudaira T, Masuda M, Ohta T, Takasu N, Mori N.

Geographic sequence variation of latent
Geographic sequence variation of latent membrane protein 1 gene of Epstein-Barr virus in Hodgkin's lymphomas
✍ Jung-Chung Lin; Seh-Ching Lin; Eng-Chun Mar; Mario Luppi; Giuseppe Torelli 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 876 KB

## Abstract To assess the role of the Epstein‐Barr virus (EBV) latent membrane protein 1 (LMP1) gene in the development of Hodgkin's lymphoma (HL), the polymorphism of this gene in EBV isolates from different geographic locations was analyzed. A 497 bp fragment spanning LMP1 gene exons 1 and 2 was

Epstein–Barr virus gene expression and l
Epstein–Barr virus gene expression and latent membrane protein 1 gene polymorphism in pediatric liver transplant recipients
✍ Beata Kasztelewicz; Irena Jankowska; Joanna Pawłowska; Joanna Teisseyre; Katarzy 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

## Abstract Immunosuppressed pediatric transplant recipients are at risk of developing Epstein–Barr virus (EBV)‐associated complications (such as post‐transplant lymphoproliferative disorders). Monitoring of the EBV DNA level in blood alone has a low predictive value for the post‐transplant course